BIBLIOGRAPHY

Adams N.G. **(2005)**, “Diagnostic use of C-reactive protein in bacteraemic emergency department patients”. *Emerg Med Austral*.,**17**, 371-375.

Agrawal A., Simpson M.J., Black S., Carey M.P., Samols D. **(2002)**, “C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide.”*J Immunol.,***169(6)**, 3217-3222.

Antonescu-Turcu A.L. and Tomic R. **(2009)**, “C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations”*CurrOpinPulmon Med.*,**15**, 120-125.

Blake G.J. and Ridker P.M. **(2003)**, ‘C-reactive protein: a surrogate risk marker or mediator of atherothrombosis”*Am J Physiol Renal Physiol*., **285(5)**, 1250-1252.

Black S., Agrawal A. and Samols D. **(2003)**, ‘The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct’. *Mol Immunol.,***39(16)**,1045-1054.

Boncler M., Luzak B., Watala C. **(2006)**, ‘Role of C-reactive protein in artherogensis’*PostepyHig Med Dosw.,***60**, 538-546.

Buckley D.I., Fu R., Freeman M., Rogers K. and Mark Helfand M. **(2009)**, “C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force”. *Ann Intern Med.,***151**,483-495.

Calabro P., Willerson J.T. and Yeh E.T.H. **(2003)**, ‘Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells”. *Circulation*, **108**, 1930-1932.

Casas J.P., Shah T., Hingorani A.D., Danesh J. and Pepys M.B. **(2008)**, “C-reactive protein and coronary heart disease” a critical review. *J Intern Med.,***264**, 295-314.

Deban L., Bottazzi B., Garlanda C., de la Torre Y.M. and Mantovani A. **(2009)**, ‘Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation”. *Biofactors*, **35(2)**, 138-145.

De Rosa S., Cirillo P., Pacileo M., Di Palma V., Paglia A. and Chiariello M. **(2009)**, “Leptin stimulated C-reactive protein production by human coronary artery endothelial cells”. *J Vasc Res*., **46(6)**, 609-617.

Di Napoli M., Schwaninger M., Cappelli R., Ceccarelli E., Di Gianfilippo G., Donati C. **(2005)**, “Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke : A statement for healthcare professionals from the CRP pooling project members”*Stroke*, **36**, 1316-1329.

Dreon D.M., Slavin J.L., Phinney S.D.**(2003)**, “Oral contraceptive use and increased plasma concentration of C-reactive protein”*Life Science*, **73(10)**, 1245-1252.

Eisenhardt S.U., Habersberger J., Murphy A., Chen Y.C., Woollard K.J., Bassler N. **(2009)**,“Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques”.*Circ Res*., **105(2)**, 128-137.

Flanders S.A., Stein J., Shochat G., Sellers K., Holland M. and Maselli J. **(2004)**, “Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough”. *Am J Med.,* **116**, 529-535.

Gonzales A.E.M., Camargo C.A., Ma J., Plautz M., Maselli J.H. and McCulloch C.E. **(2011)**, “C-Reactive protein testing does not decrease antibiotic use for acute cough illness when compared to a clinical algorithm”. *J Emerg Med.,***41**, 1-7.

Gould J.M. and Weiser J.N. **(2001)**, 'Expression of C-reactive protein in the human respiratory tract". *Infect Immun.,***69(3)**,1747-1754.

Hage F.G. and Szalai A.J. **(2009)**, "The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk". *CurrAtheroscler Reps*., **11(2)**, 124-130.

Hemingway H., Philipson P., Chen R., Fitzpatrick N.K., Damant J. and Shipley M. **(2010)**," Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease". *PLoS Med.,***7(6)**, 1-11.

Ho K.M. **(2009)**, "An update on C-reactive protein for intensivists'. *Anaesth Intensive Care.,***37**, 234-241.

Jialal I., Devaraj S., Venugopal S.K.**(2004)**,"C-reactive protein: risk marker or mediator in atherothrombosis"*Hypertension,***44(1)**, 6-11.

Ji S.R., Wu Y., Potempa L.A., Liang Y.H., Zhao J.**(2006)**,"Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions". *ArteriosclerThrombVascBiol*.,**26(4)**, 935- 941.

Lakka H.M., Lakka T.A., Rankinen T. **(2006)**, "The TNF-α G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study". *Vascular Pharmacology,***44(5)**, 377- 383.

Lee C.C., Hong M.Y., Lee N.Y., Chen P.L., Chang C.M. and Ko W.C. **(2012)**, "Pitfalls in using serum C-reactive protein to predict bacteremia in febrile adults in the ED". *Am J Emerg Med*., **30**, 562-569.

Logering B.A., Gerke P., Kreft B., Wolber E.M., Klinger M.H. and Fricke L. **(2003)**, "The kidney as a second site of human C-reactive protein formation in vivo". *Euro J Immunol*.,**33**, 152-161.

McLaughlin T., Abbasi F., Lamendola C., Liang L., Reaven G., Schaaf P. **(2002)**, "Differentiation between obesity and insulin resistance in the association with C-reactive protein". *Circulation*, **106**, 2908-2912.

Michael E. **(2008)**, "A persistently elevated C-reactive protein level in pneumonia may indicate empyema". *Critical Care.,***12**, 1-2.

Mitaka C. **(2005)**, "Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome". *ClinChimActa.,***351**,17-29.

Paul A., Yeh E.T., Chan L.**(2005)**,"A proatherogenic role for C-reactive protein in vivo". *CurrOpinLipidol*.,**16(5)**, 512-517.

Pierrakos C. and Vincent J.L. **(2010)**, "Sepsis biomarkers: a review". *Crit Care.,***14**, 1-18.

Povoa P. **(2002)**, "C-reactive protein: a valuable marker of sepsis". *Intensive Care Med.,***28**, 235-43.

Ridker P.M., Danielson E., Fonseca F.A.H., Genest F., Gotto A.M. and Jr, Kastelein J.J.P. **(2008)**, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". *N Engl J Med.,***359**, 2195-2207.

Santos I.S., Bensenor I.M., Machado J.B., Fedeli L.M. and Lotufo P.A. **(2012)**, "Intervention to reduce C-reactive protein determination request for acute infections at an emergency department". *Emerg Med J*.,**29(12)**, 965-968.

Smitha C.N., Soni S. and Basu S.K. **(2011)**, “Role of C-reactive protein and periodontal disease in systemic health”: A review. *J Adv Dent Res*., **2(1)**, 1-5.

Stolz D., Christ-Crain M., Morgenthaler N.G., Leuppi J., Miedinger D. and Bingisser R. **(2007)**, Copeptin, “C-reactive protein and procalcitonin as prognostic biomarkers in acute exacerbation of COPD”. *Chest.*,**131**, 1058-1067.

Szalai A.J., Wu J., Lange E.M., McCrory M.A., Langefeld and Williams A. **(2005)**, “Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level”. *J Mol Med*., **83(6)**, 440-447.

Venugopal S.K., Devaraj S. and Jialal I. **(2005)**, “Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells. Potential for paracrine/autocrine effects”. *Am J Pathol*.,**166(4)**, 1265-1271.

Verma S. and Yeh E.T.H. **(2003)**, “C-reactive protein and atherothrombosis- Beyond a biomarker: an actual partaker of lesion formation”. *Am J PhysiolRegulIntegr Comp Physiol*., **285**, 1253–1256.

Wu H.P., Lin C.Y., Chang C.F., Changc Y.J. and Huang C.Y. **(2005)**, “Predictive value of C-reactive protein at different cutoff levels in acute appendicitis”. *Am J Emerg Med.,* **23**, 449-453.

Yeh E.T.H. **(2014)**, “A new perspective on the biology of C-reactive protein”. *Circul Res*., **97**, 609-611.

Zouki C., Haas B., Chan J.S., Potempa L.A. and Filep J.G. **(2001)**, “Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion”. *J Immunol*.,**167(9)**, 5355-5361.